Astrazeneca
IMFINZI
Manufacturer:
Astrazeneca
Name:
IMFINZI
HCPCS Code Descriptor:
Injection, durvalumab, 10 mg
Category:
J Code
HCPCS:
J9173
NDC(s):
00310-4611-50, 00310-4500-12
Primary Type:
Oncology
Generic Status:
Single-Source
Route of Administration:
Intravenous
About:
IMFINZI is an Oncology drug manufactured by Astrazeneca and administered via the Intravenous route of administration. The J Code: J9173 is aligned to the drug IMFINZI.
Imfinzi works by blocking a protein on the surface of cancer cells called PD-L1. Imfinzi is administered via intravenous infusion over a one-hour time frame. Imfinzi was previously aligned to the temporary HCPCS C9492 before receiving the permanent HCPCS J9173. Patient support for this medication can be found through the Astrazeneca Pharmaceuticals AZ & Me prescription savings program and others.
Access Pricing and More By Registering
HCPCS Added Date:
1/1/19
HCPCS Effective Date:
1/1/19
HCPCS Short Description:
Inj., durvalumab, 10 mg
Billing and Coding Guide:
https://www.imfinzihcp.com/content/dam/website-services/us/434-imfinzi-com/pdf/DURVALUMAB_stageIII_NSCLC_coding_resource.PDF
Patient Assistance:
https://www.azandmeapp.com/prescriptionsavings/
https://www.myaccess36.com/imfinzi-durvalumab.html